natgillin/translations-raw huggingface dataset:
Efficacy and safety has not been demonstrated in the paediatric population below 18 years of age and no recommendation on a posology can be made (see section 4.2).
Varnost in učinkovitost pri pediatrični populaciji, mlajši od 18 let, nista bili dokazani, zato priporočil glede odmerjanja ni mogoče dati (glejte poglavje 4.2).
Efficacy and safety have not been established in non-CF bronchiectasis patients.
Varnost in učinkovitost zdravila pri bolnikih z bronhiektazijo, ki ni posledica CF, nista bili dokazani.
Efficacy and Safety in Acute Coronary Syndrome (ACS)
Učinkovitost in varnost pri akutnem koronarnem sindromu (ACS)
Efficacy and safety in elderly > 65 years have not been established.
Učinkovitosti in varnosti pri bolnikih, starejših od 65 let niso dokazali.
Efficacy and safety in elderly > 65 years have not been established.
Učinkovitosti in varnosti pri bolnikih, starejših od 65 let, niso dokazali.
Efficacy and safety in patients below 18 years has not been established.
Učinkovitost in varnost pri bolnikih, mlajših od 18 let, nista dokazani.
Efficacy and safety in patients below 18 years has not been studied.
Učinkovitost in varnost pri bolnikih, mlajših od 18 let, nista raziskani.
Efficacy and safety of 120 mg XGEVA SC every 4 weeks or 4 mg zoledronic acid (dose-adjusted for reduced renal function) IV every 4 weeks were compared in three randomised, double blind, active controlled studies, in IV-bisphosphonate naïve patients with advanced malignancies involving bone: adults with breast cancer (study 1), other solid tumours or multiple myeloma (study 2), and castrate- resistant prostate cancer (study 3).
Učinkovitost in varnost 120 mg zdravila XGEVA s.c. na 4 tedne ali 4 mg zoledronske kisline (odmerek prilagojen na zmanjšano delovanje ledvic) i.v. na 4 tedne so primerjali v treh randomiziranih, dvojno slepih, z zdravilno učinkovino kontroliranih študijah bolnikov, ki še niso dobivali intravenskega bisfosfonata in so imeli napredovane malignome, ki so zajeli kosti: odrasle z rakom dojke (študija 1), drugimi solidnimi tumorji ali diseminiranim plazmocitomom (študija 2) in proti kastraciji odpornim rakom prostate (študija 3).
Efficacy and safety of Ameluz has been evaluated in 644 patients enrolled in clinical trials.
Učinkovitost in varnost zdravila Ameluz so ocenjevali pri 644 bolnikih, vključenih v klinična preskušanja.
Efficacy and safety of Fabrazyme was evaluated in one study with children, one dose-finding study, two double-blind placebo-controlled studies, and one open-label extension study in both male and female patients.
Učinkovitost in varnost zdravila Fabrazyme je bila ovrednotena med eno študijo pri otrocih, eno študijo ugotavljanja odmerka, dvema dvojno slepima s placebom nadzorovanima študijama in eno razširjeno študijo odprtega tipa pri moških in ženskih bolnikih.
Efficacy and safety of HyQvia was assessed in a phase 3 study (160603) in 83 patients with PID.
Učinkovitost in varnost zdravila HyQvia je bila ocenjena v študiji 3. faze (160603) pri 83 bolnikih s PID.
Efficacy and safety of Intrinsa in naturally menopausal women with HSDD on concomitant estrogen, with or without progestogen, have not been evaluated.
Učinkovitosti in varnosti zdravila Intrinsa pri ženskah po naravni menopavzi s HSDD, ki sočasno uporabljajo estrogen, s progestagenom ali brez njega, niso ocenili.
Efficacy and safety of irbesartan/hydrochlorothiazide as initial therapy for severe hypertension (defined as SeDBP  110 mmHg) was evaluated in a multicenter, randomised, double-blind, active-controlled, 8-week, parallel-arm study.
Učinkovitost in varnost kombinacije irbesartana in hidroklorotiazida kot začetnega zdravila za zdravljenje hude hipertenzije (definirana kot diastolični tlak v sedečem položaju (SeDBP) ≥ 110 mmHg) sta bili ovrednoteni z multicentrično, randomizirano, dvojno slepo, z učinkovino nadzorovano, 8-tedensko študijo paralelnih skupin.
Efficacy and safety of Livensa in naturally menopausal women with HSDD on concomitant estrogen, with or without progestogen, have not been evaluated.
Učinkovitosti in varnosti zdravila Livensa pri ženskah po naravni menopavzi s HSDD, ki sočasno uporabljajo estrogen, s progestagenom ali brez njega, niso ocenili.
Efficacy and safety of Myocet in the adjuvant treatment of breast cancer have not been determined.
Učinkovitosti in varnosti zdravila Myocet pri pomožnem zdravljenju raka dojke niso določili.
Efficacy and safety of Spectrila was compared to a native E. coli-asparaginase (reference medicinal product) in a randomised double-blinded clinical trial (study MC-ASP.5/ALL; based on ALL treatment protocol DCOG ALL10) in 199 children/adolescents aged 1 – 18 years with de novo ALL.
Učinkovitost in varnost zdravila Spectrila so primerjali z nativno asparaginazo E. coli (referenčno zdravilo) v randomiziranem dvojno slepem kliničnem preskušanju (študija MC-ASP.5/ALL; na podlagi protokola zdravljenja ALL DCOG ALL10) pri 199 otrocih/mladostnikih, starih 1-18 let z de novo ALL.
Efficacy and safety of the combination of irbesartan and hydrochlorothiazide as initial therapy for severe hypertension (defined as SeDBP ≥ 110 mmHg) was evaluated in a multicenter, randomized, double-blind, active-controlled, 8-week, parallel-arm study.
Učinkovitost in varnost kombinacije irbesartana in hidroklorotiazida kot začetnega zdravila za zdravljenje hude hipertenzije (definirana kot diastolični tlak v sedečem položaju /SeDBP/ ≥ 110 mm Hg) sta bili ovrednoteni z multicentrično randomizirano dvojno slepo z učinkovino nadzorovano 8- tedensko študijo paralelnih skupin.
Efficacy and safety of vinflunine have not been studied in patients with performance status  2.
Učinkovitost in varnost vinflunina nista bili preučeni pri bolnikih s telesno zmogljivostjo  2.
Efficacy and safety of Xarelto has been investigated in combination with the antiplatelet agents aspirin and clopidogrel/ticlopidine.
Učinkovitost in varnost zdravila Xarelto so preučevali v kombinaciji z antitrombotiki kot so acetilsalicilna kislina in klopidogrel/tiklopidin.
Efficacy and safety were measured from the time of randomisation after completion of first line (induction) therapy.
Učinkovitost in varnost so merili od časa randomizacije po zaključku terapije prve izbire (indukcijske terapije).
Efficacy and safety were measured from the time of randomisation after completion of first-line (induction) therapy.
Učinkovitost in varnost so merili od časa randomizacije po zaključku terapije prvega izbora (indukcijske terapije).
Efficacy and/or immunogenicity of Gardasil 9 were assessed in eight clinical studies.
Učinkovitost in/ali imunogenost cepiva Gardasil 9 so ovrednotili v osmih kliničnih študijah.
Efficacy at 2 years (95% CI)
učinkovitosti po 2 letih (95- odstotni IZ)
Efficacy beyond three months has not been demonstrated in placebo-controlled studies (see section 5.1).
Učinkovitost zdravljenja, daljšega od treh mesecev, ni bila dokazana v študijah, nadzorovanih s placebom (glejte poglavje 5.1).
Efficacy data from randomised Phase 3 Study 1014 are summarised in Table 4, and the Kaplan-Meier curves for PFS and overall survival (OS) are shown in Figure 1 and 2, respectively.
Podatki o učinkovitosti iz randomizirane študije 3. faze, Študije 1014, so povzeti v preglednici 4, Kaplan-Meierjevi krivulji za PFS in skupno preživetje (OS – OverallSsurvival) pa sta prikazani na slikah 1 in 2.
Efficacy data have shown that a vaccinated dog has 3.6 times less risk to develop an active infection and 4 times less risk to develop a clinical disease than a non-vaccinated dog, on dogs submitted to multiple natural parasite exposure in zones with high infection pressure.
Podatki o učinkovitosti pri psih, ki so bili izpostavljeni številnim naravnim parazitom na območjih, kjer je okuženost zelo razširjena, kažejo, da imajo cepljeni psi 3-krat manj možnosti, da bi se okužili in 4- krat manj možnosti, da bi razvili bolezen, kot necepljeni psi.
Efficacy data have shown that a vaccinated dog has 3.6 times less risk to develop an active infection and 4 times less risk to develop a clinical disease than a non-vaccinated dog, on dogs submitted to multiple natural parasite exposure in zones with high infection pressure.
Podatki o učinkovitosti pri psih, ki so bili izpostavljeni številnim naravnim parazitom na območjih, kjer je okuženost zelo razširjena, kažejo, da imajo cepljeni psi 3-krat manj možnosti, da bi se okužili in 4- krat manj možnosti, da bi razvili bolezen, kot necepljeni psi..
Efficacy data in patients with CML in blast crisis are not available.
Podatki o učinkovitosti pri bolnikih s KML v blastni krizi niso dostopni.
Efficacy data in subgroups comparing the 2 vs 10 mg/kg Q3W from P001, using the data cut-off date of 18-Oct-2014 from Parts B2 and D of P001 by dose level.
Podatke o varnosti v podskupinah za primerjavo 2 proti 10 mg/kg vsake 3 tedne iz študije P001, upoštevajoč presečni datum (cut-off)
Efficacy data were collected and analyzed through week 8 for both studies.
Predklinični podatki o varnosti
Efficacy data were collected and analyzed through week 8 for both studies.
Primerjali so učinkovitost in varnost ustekinumaba in etanercepta.
Efficacy data, both overall and by various subgroups, are presented below in Table 3.
Podatki o učinkovitosti, tako celotni kot po raznih podskupinah, so zajeti spodaj v preglednici 3.
Efficacy endpoint
cilj opazovanja glede učinkovitosti
Efficacy endpoint
Cilj opazovanja za oceno učinkovitosti
Efficacy endpoint
Učinkovitost
Efficacy endpoint or haematological parametera
Končna točka učinkovitosti ali hematološki parametera
Efficacy endpoint or haematological parametera
Kriterij učinkovitosti ali hematološki parametera
Efficacy endpointb
cilj študije učinkovitostib
Efficacy endpoints
Cilji opazovanja za oceno učinkovitosti
Efficacy endpoints for the docetaxel arms versus the control arm are summarized in the following table:
Končna učinkovitost docetakselovih krakov v primerjavi s kontrolnim krakom je povzeta v spodnji tabeli:
Efficacy endpoints for the docetaxel arms versus the control arm are summarized in the following table:
Končna učinkovitost docetakselovih krakov v primerjavi s kontrolnimi kraki je povzeta v spodnji tabeli:
Efficacy endpoints for the docetaxel arms versus the control arm are summarized in the following table:
Končna učinkovitost docetakselovih rok v primerjavi s kontrolno roko je povzeta v spodnji tabeli:
Efficacy endpoints for the docetaxel arms versus the control arm are summarized in the following table:
Končna učinkovitost rok z docetaksel v primerjavi s kontrolno roko je povzeta v spodnji tabeli:
Efficacy endpoints for the docetaxel arms versus the control arm are summarized in the following table:
Končna učinkovitost rok z zdravilom Docetaxel Winthrop v primerjavi s kontrolno roko je povzeta v spodnji tabeli:
Efficacy endpoints for the docetaxel arms versus the control arm are summarized in the following table:
Končne točke učinkovitosti krakov z docetakselom v primerjavi s kontrolnim krakom so povzete v spodnji razpredelnici:
Efficacy evaluation of Gardasil 9 against cervical high grade diseases caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in the PPE
Ovrednotenje učinkovitosti cepiva Gardasil 9 proti bolezni materničnega vratu visoke stopnje, ki jo povzročajo tipi HPV 6, 11, 16, 18, 31, 33, 45, 52 in 58, v PPE
Efficacy findings were consistent, independent of the infective Candida species, primary site of infection and neutropenic status (see Table).
Podatki o učinkovitosti so bili skladni, ne glede na vrsto gliv Candida, ki je povzročila okužbo, primarno mesto okužbe in stanje nevtropenije (glejte tabelo).
Efficacy for patients identified within the Phase 1/2 study population who failed either imatinib alone or imatinib in addition to one or both second-generation TKIs (dasatinib and nilotinib) and for whom, based on the presence of co-morbidities, a history of TKI intolerance, or a BCR-ABL resistance mutation, the remaining approved TKI(s) are not considered appropriate treatment options was reviewed.
Ocenili so učinkovitost pri bolnikih, ki so jih identificirali med populacijo v 1./2. fazi in pri katerih zdravljenje z imatinibom samim ali imatinibom ter enim ali obema TKI druge generacije (dasatinib in nilotinib) ni bilo uspešno in za katere (glede na sočasno prisotne bolezni, anamnezo neprenašanja TKI ali mutacijo BCR-ABL, ki je povzročila neodzivnost) preostali odobreni TKI niso primerna terapevtska možnost.
Efficacy has been demonstrated in clinical studies against the following pathogens that were susceptible to oritavancin in vitro.
Učinkovitost je bila dokazana v kliničnih študijah za naslednje patogene, ki so bili in vitro dovzetni za oritavancin.
Efficacy has been demonstrated in clinical studies against the pathogens listed under each indication that were susceptible to ceftaroline in vitro.
Učinkovitost je bila v kliničnih študijah dokazana proti patogenom, ki so našteti pri posamezni indikaciji in so bili in vitro občutljivi za ceftarolin.
Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer's Disease Cooperative Study- Clinician's Global Impression of Change).
Učinkovitost so pokazali z dvema neodvisnima lestvicama, s katerima so stanje bolnikov ocenjevali v rednih presledkih med 6-mesečnim obdobjem zdravljenja, kot je prikazano v tabeli 5 spodaj: ADAS-Cog, meritev kognicije in globalna meritev ADCS-CGIC (Kooperativna študija Alzheimerjeve bolezni – zdravnikov globalni vtis o spremembi - Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change).
Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer's Disease Cooperative Study- Clinician's Global Impression of Change).
Učinkovitost so prikazali z dvema neodvisnima lestvicama, s katerima so stanje bolnikov ocenjevali v rednih presledkih med 6-mesečnim obdobjem zdravljenja, kot je prikazano v tabeli 5 spodaj: ADAS-Cog, meritev kognicije in globalna meritev ADCS-CGIC (Kooperativna študija Alzheimerjeve bolezni – zdravnikov globalni vtis o spremembi - Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change).
Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer’s Disease Cooperative Study- Clinician’s Global Impression of Change).
Učinkovitost so dokazali z uporabo dveh neodvisnih lestvic, s katerima so bolnike ocenjevali v rednih presledkih med 6- mesečnim obdobjem zdravljenja, kot kaže Preglednica 5 spodaj: ADAS-Cog, merilo kognitivne zmogljivosti, in globalno merilo ADCS-CGIC (Alzheimer’s Disease Cooperative Study-Clinician’s Global Impression of Change /Kooperativna študija Alzheimerjeve bolezni-globalni klinični vtis sprememb).
Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer’s Disease Cooperative Study- Clinician’s Global Impression of Change).
Učinkovitost so dokazali z uporabo dveh neodvisnih lestvic, s katerima so bolnike ocenjevali v rednih presledkih med 6-mesečnim obdobjem zdravljenja, kot kaže preglednica 5 spodaj: ADAS-Cog, merilo za kognicijo, in globalno merilo ADCS-CGIC (Alzheimer’s Disease Cooperative Study-Clinician’s Global Impression of Change /Kooperativna študija Alzheimerjeve bolezni-globalni klinični vtis sprememb).
Efficacy has been evaluated on the basis of preliminary results in chickens.
Učinkovitost je ocenjena na podlagi predhodnih rezultatov pri piščancih.
Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease (see section 5.1).
Učinkovitost zdravila je bila dokazana pri bolnikih s PAH, z etiologijo idiopatske ali dedne PAH ali PAH, povezane z boleznijo veziva (glejte poglavje 5.1).
Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease (see section 5.1).
Učinkovitost je bila ugotovljena v populaciji s PAH, vključno z idiopatično in dedno PAH, PAH, povezano z boleznimi vezivnega tkiva, in PAH, povezano z zdravljeno preprosto prirojeno boleznijo srca (glejte poglavje 5.1).
Efficacy has only been tested in conjunction with surgery and radiotherapy; therefore the treatment should be conducted according to treatment course described in section “Dosage for each species, route and method of administration”.
Učinkovitost je bila preskušena le v povezavi z operativnim zdravljenjem in radioterapijo, zato je potrebno zdraviti v skladu s potekom zdravljenja, ki je opisan v poglavju « ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) IN NAČIN UPORABE ZDRAVILA ».
Efficacy in 16-26 year-old women and men
Učinkovitost pri ženskah in moških, starih od 16 do 26 let
Efficacy in 24-45 year-old women
Učinkovitost pri ženskah, starih od 24 do 45 let
Efficacy in adult patients with pulmonary arterial hypertension
Učinkovitost pri odraslih bolnikih s pljučno arterijsko hipertenzijo
Efficacy in adult patients with pulmonary hypertension
Učinkovitost pri odraslih bolnikih s pljučno hipertenzijo
Efficacy in adults with HCV/HIV-1 co-infection Study 110
Učinkovitost pri odraslih bolnikih s sočasno okužbo s HCV/ HIV-1 Študija 110
Efficacy in autoantibody (RF and or anti-CCP) seropositive patients
Učinkovitost pri serološko pozitivnih (RF in/ali anti-CCP) bolnikih
Efficacy in HIV infected subjects
Učinkovitost pri osebah, okuženih s HIV
Efficacy in patients who developed atrial fibrillation post cardiac surgery (ACT II)
Učinkovitost pri bolnikih, ki se jim je atrijska fibrilacija pojavila po kardiokirurškem posegu (ACT II) Učinkovitost pri bolnikih z atrijsko fibrilacijo po kardiokirurškem posegu so raziskali v študiji ACT II.
Efficacy in patients with HCV genotype 1 and HIV-1 co-infection
Učinkovitost pri bolnikih z okužbo s HCV genotipa 1 in sočasno okužbo s HIV-1
Efficacy in patients with HCV genotype 4 infection
Učinkovitost pri bolnikih, okuženih s HCV genotipa 4
Efficacy in patients with pulmonary arterial hypertension (PAH)
Učinkovitost pri bolnikih s pljučno arterijsko hipertenzijo (PAH)
Efficacy in patients with sustained atrial fibrillation, (ACT I and ACT III)
Učinkovitost pri bolnikih z obstojno atrijsko fibrilacijo (ACT I in ACT III)
Efficacy in previously treated adults Study C216 (REALIZE)
Učinkovitost zdravila pri predhodno zdravljenih odraslih Študija C216 (REALIZE)
Efficacy in the patient population targeted in this SmPC
Učinkovitost v populaciji bolnikov, na katero je osredotočen ta povzetek glavnih značilnosti zdravila
Efficacy in treatment-experienced patients with HCV genotype 1 infection
Učinkovitost pri predhodno zdravljenih bolnikih, okuženih s HCV genotipa 1
Efficacy in treatment-naïve adults Study C211
Učinkovitost zdravila pri še nezdravljenih odraslih bolnikih Študija C211
Efficacy in treatment-naïve patients with HCV genotype 1 infection
Učinkovitost pri predhodno nezdravljenih bolnikih, okuženih s HCV genotipa 1
Efficacy is based on time to tumour progression (TTP) and an increase in survival in GIST, on progression free survival and objective response rates for treatment-naïve and cytokine-refractory MRCC respectively, and on progression free survival for pNET.
Učinkovitost temelji na času do napredovanja tumorja in podaljšanju preživetja pri GIST, na preživetju brez napredovanja bolezni pri še nezdravljenem MRCC, na objektivnem odzivu na zdravljenje pri MRCC, odpornemu proti citokinom in na preživetju brez napredovanja bolezni pri pNET.
Efficacy of a single 30-minute application of Qutenza to the feet has been shown in controlled clinical trials conducted in patients with painful Human Imunodeficiency Virus – Associated Neuropathy (HIV-AN) and painful diabetic peripheral neuropathy.
Učinkovitost enkratne 30 minut trajajoče uporabe zdravila Qutenza na stopalih je bila dokazana v kontroliranih kliničnih preskušanjih z bolniki z bolečo nevropatijo, povezano z virusom humane imunske pomanjkljivosti (HIV-AN - Human Imunodeficiency Virus – Associated Neuropathy) in bolečo diabetično periferno nevropatijo.
Efficacy of ALIMTA + cisplatin vs. gemcitabine + cisplatin in first-line non-small cell lung cancer – ITT population and histology subgroups.
Učinkovitost zdravila ALIMTA skupaj s cisplatinom proti gemcitabinu skupaj s cisplatinom pri zdravljenju prvega izbora nedrobnoceličnega karcinoma pljuč – NZ populacija in histološke podskupine
Efficacy of ALIMTA plus cisplatin vs. cisplatin in malignant pleural mesothelioma
Učinkovitost zdravila ALIMTA skupaj s cisplatinom v primerjavi s cisplatinom pri malignem plevralnem mezoteliomu
Efficacy of ALIMTA vs docetaxel in NSCLC - ITT population
Učinkovitost zdravila ALIMTA v primerjavi z docetakselom pri NSCLC - Populacija NZ
Efficacy of Betmiga was evaluated in three phase 3 randomized, double blind, placebo controlled, 12- week studies for the treatment of overactive bladder with symptoms of urgency and frequency with or without incontinence.
Učinkovitost zdravila Betmiga so ocenili v treh 12-tedenskih, dvojno slepih, s placebom kontroliranih študijah 3. faze za zdravljenje prekomerno aktivnega sečnega mehurja s simptomi urgentne mikcije in pogostnosti, z inkontinenco ali brez nje.
Efficacy of combination therapy on the primary endpoint was consistent on the comparison to individual monotherapy and across the subgroups of age, ethnic origin, geographical region, aetiology (iPAH /hPAH and PAH-CTD).
Učinkovitost kombiniranega zdravljenja na primarni opazovani dogodek se je skladala s primerjavo z vsako posamezno monoterapijo in v podskupinah po starosti, etničnem izvoru, geografski regiji in etiologiji (iPAH/hPAH in PAH-CTD).
Efficacy of darunavir 800 mg once daily co-administered with 150 mg cobicistat once daily in ART-naïve and ART-experienced patients
Učinkovitost darunavirja 800 mg enkrat na dan skupaj s 150 mg kobicistata enkrat na dan, pri bolnikih brez izkušenj z ART in pri bolnikih z izkušnjami z ART
Efficacy of docetaxel in the induction treatment of patients with inoperable locally advanced SCCHN (Intent-to-Treat Analysis)
Učinkovitost docetaksela pri zdravljenju bolnikov z adenokarcinomom želodca
Efficacy of docetaxel in the induction treatment of patients with inoperable locally advanced SCCHN (Intent-to-Treat Analysis)
Učinkovitost docetaksela za indukcijsko zdravljenje bolnikov z inoperabilnim lokalno napredovalim SCCHN (analiza z namenom zdravljenja)
Efficacy of docetaxel in the induction treatment of patients with locally advanced SCCHN (Intent-to- Treat Analysis)
Učinkovitost docetaksela v indukcijskem zdravljenju bolnikov z lokalno napredovalim SCCHN (analiza z namenom zdravljenja)
Efficacy of docetaxel in the induction treatment of patients with locally advanced SCCHN (Intent-to- Treat Analysis)
Učinkovitost docetaksela v indukcijskem zdravljenju bolnikov z lokalno napredovalim SCCHN (analiza z-namenom-zdravljenja)
Efficacy of docetaxel in the induction treatment of patients with locally advanced SCCHN (Intent-to- Treat Analysis)
Učinkovitost docetaksela v indukcijskem zdravljenju bolnikov z lokalno napredovalim SCCHN (analiza znamenomzdravljenja)
Efficacy of docetaxel in the induction treatment of patients with locally advanced SCCHN (Intent-to-Treat Analysis)
Učinkovitost zdravila docetaksel za indukcijsko zdravljenje bolnikov z inoperabilnim lokalno
Efficacy of docetaxel in the induction treatment of patientswith locally advanced SCCHN (Intent-to- Treat Analysis)
Učinkovitost docetaksela v indukcijskem zdravljenju bolnikov z lokalno napredovalim SCCHN (analiza z namenom zdravljenja)